Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States
Pharmacoepidemiology · 2022
DOI: 10.3390/pharma1030010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology, 2022. Verfasst von Tianyu Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH).
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Opioid use disorder (OUD) is a chronic disease requiring long-term treatment and is associated with opioid overdose and increased risk of mortality. However, existing randomized clinical trials focused on short-term treatment engagement and detoxification rather than overdose or mortality risk due to limited follow-up time and ethical considerations. We used a hypothetical trial framework to conduct a retrospective cohort study to assess the effectiveness of time-varying buprenorphine-naloxone on opioid overdose and death. We identified 58,835 insured adult patients with OUD diagnosis in the US, 2010–2017. We fit a marginal structural model using inverse probability weighting methods to account for measured baseline and time-varying confounders, as well as selection bias due to possibly differential loss-to-follow-up. We found that receipt of buprenorphine-naloxone was associated with reduced risk of opioid overdose (hazard ratio (HR) = 0.66, 95% confidence interval (CI): 0.49, 0.91), death (HR = 0.24, 95% CI: 0.08, 0.75), and overdose or death (HR = 0.58, 95% CI: 0.40, 0.84). The E-value for death was 7.8, which was larger than the upper 95% CI of the association between each measured baseline variable and all-cause death, which implies that the unmeasured confounding itself may not explain away the estimated effect of treatment on the endpoint of all-cause mortality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA.
- Department of Computer Science and Statistics, College of Art and Science, University of Rhode Island, Kingston, RI 02881, USA.
- Department of Epidemiology, Brown University School of Public Health, Providence, RI 02903, USA.
- The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
ORCID-Profile: Tianyu Sun, Jeffrey Bratberg
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH)
Zitieren
APA
Sun, T., Katenka, N., Kogut, S., Bratberg, J., Rich, J., & Buchanan, A. (2022). Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States. Pharmacoepidemiology. https://doi.org/10.3390/pharma1030010
Vancouver
Sun T, Katenka N, Kogut S, Bratberg J, Rich J, Buchanan A. Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States. Pharmacoepidemiology. 2022. doi:10.3390/pharma1030010
BibTeX
@article{Sun2022,
author = {Sun, Tianyu and Katenka, Natallia and Kogut, Stephen and Bratberg, Jeffrey and Rich, Josiah and Buchanan, Ashley},
title = {Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States},
journal = {Pharmacoepidemiology},
year = {2022},
doi = {10.3390/pharma1030010}
}
EUVIMED